{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:08:26Z","timestamp":1758125306855},"reference-count":34,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.3892\/or.2013.2959","type":"journal-article","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T09:00:43Z","timestamp":1389085243000},"page":"1453-1458","source":"Crossref","is-referenced-by-count":4,"title":["Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo"],"prefix":"10.3892","volume":"31","author":[{"given":"HIROKAZU","family":"NAGAI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAKO","family":"FUJIOKA-KOBAYASHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GO","family":"OHE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KANAE","family":"HARA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NATSUMI","family":"TAKAMARU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DAISUKE","family":"UCHIDA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TETSUYA","family":"TAMATANI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KENJI","family":"FUJISAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOUJI","family":"MIYAMOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,12,31]]},"reference":[{"key":"key20180107222224_b1-or-31-03-1453","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1034\/j.1601-0825.2002.02870.x","article-title":"Salivary gland tumors","volume":"8","author":"Speight","year":"2002","journal-title":"Oral Dis"},{"key":"key20180107222224_b2-or-31-03-1453","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11912-012-0220-5","article-title":"Salivary gland cancers: biology and molecular targets for therapy","volume":"14","author":"Bell","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"key20180107222224_b3-or-31-03-1453","doi-asserted-by":"crossref","first-page":"602","DOI":"10.5858\/2010-0655-RAIR.1","article-title":"An update on molecular diagnostics of squamous and salivary gland tumors of the head and neck","volume":"135","author":"Hunt","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"key20180107222224_b4-or-31-03-1453","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.2005.05.3025","article-title":"Systemic therapy in the palliative management of advanced salivary gland cancers","volume":"24","author":"Laurie","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20180107222224_b5-or-31-03-1453","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.critrevonc.2009.10.004","article-title":"Major and minor salivary gland tumors","volume":"74","author":"Guzzo","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20180107222224_b6-or-31-03-1453","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1054\/bjoc.2001.1762","article-title":"Malignant tumours of the salivary glands","volume":"84","author":"Bensadoun","year":"2001","journal-title":"Br J Cancer"},{"key":"key20180107222224_b7-or-31-03-1453","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/sj.bjc.6603132","article-title":"Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01","volume":"94","author":"Yeow","year":"2006","journal-title":"Br J Cancer"},{"key":"key20180107222224_b8-or-31-03-1453","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/pros.20587","article-title":"Multiple molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo","volume":"67","author":"Shabbeer","year":"2007","journal-title":"Prostate"},{"key":"key20180107222224_b9-or-31-03-1453","first-page":"1273","article-title":"Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells","volume":"2","author":"Rosato","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"key20180107222224_b10-or-31-03-1453","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0092-8674(94)90229-1","article-title":"Transcription: in tune with the histones","volume":"77","author":"Wolffe","year":"1994","journal-title":"Cell"},{"key":"key20180107222224_b11-or-31-03-1453","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1124\/mol.65.3.571","article-title":"Evidence of a functional role for p21WAF1\/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol","volume":"65","author":"Rosato","year":"2004","journal-title":"Mol Pharmacol"},{"key":"key20180107222224_b12-or-31-03-1453","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/cncr.21589","article-title":"Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia","volume":"104","author":"Bug","year":"2005","journal-title":"Cancer"},{"key":"key20180107222224_b13-or-31-03-1453","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"key20180107222224_b14-or-31-03-1453","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.thorsurg.2006.07.005","article-title":"Targeting the epigenome for the treatment of thoracic malignancies","volume":"16","author":"Schrump","year":"2007","journal-title":"Thorac Surg Clin"},{"key":"key20180107222224_b15-or-31-03-1453","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1073\/pnas.191208598","article-title":"The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species","volume":"98","author":"Ruefli","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107222224_b16-or-31-03-1453","first-page":"399","article-title":"Histone deacetylase inhibitors as potential anti-skin cancer agents","volume":"59","author":"Saunders","year":"1999","journal-title":"Cancer Res"},{"key":"key20180107222224_b17-or-31-03-1453","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"De Ruijter","year":"2002","journal-title":"Biochem J"},{"key":"key20180107222224_b18-or-31-03-1453","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1073\/pnas.96.9.4868","article-title":"Three proteins define a class of human histone deacetylases related to yeast Hda1p","volume":"96","author":"Grozinger","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107222224_b19-or-31-03-1453","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/med.10017","article-title":"Anti-tumor mechanisms of valproate: a novel role for an old drug","volume":"22","author":"Blaheta","year":"2002","journal-title":"Med Res Rev"},{"key":"key20180107222224_b20-or-31-03-1453","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02899028","article-title":"Generation of ceils with phenotypes of both intercalated duct-type and myoepithelial cells in human parotid gland adenocarcinoma clonal cells grown in a thymic nude mice","volume":"51","author":"Yanagawa","year":"1986","journal-title":"Virchows Arch"},{"key":"key20180107222224_b21-or-31-03-1453","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/1097-0142(19810801)48:3<745::AID-CNCR2820480314>3.0.CO;2-7","article-title":"Aneoplastic epithelial duct cell line established from an irradiated human salivary gland","volume":"48","author":"Shirasuna","year":"1981","journal-title":"Cancer"},{"key":"key20180107222224_b22-or-31-03-1453","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0901-5027(05)80830-6","article-title":"Selection of adenoid cystic carcinoma cell clone highly metastatic to the lung: an experimental study","volume":"26","author":"Guan","year":"1997","journal-title":"Int J Oral Maxillofac Surg"},{"key":"key20180107222224_b23-or-31-03-1453","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/sj.bjc.6602004","article-title":"Frequent downregulation of 14-3-3 \u03c3 protein and hypermethylation of 14-3-3 \u03c3 gene in salivary gland adenoid cystic carcinoma","volume":"91","author":"Uchida","year":"2004","journal-title":"Br J Cancer"},{"key":"key20180107222224_b24-or-31-03-1453","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1476-4598-8-62","article-title":"Vesnarinone downregulates CXCR4 expression via upregulation of Kruppel-like factor 2 in oral cancer cells","volume":"8","author":"Uchida","year":"2009","journal-title":"Mol Cancer"},{"key":"key20180107222224_b25-or-31-03-1453","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00280-010-1287-z","article-title":"The histone deacetylase inhibitor varproic acid sensitizes human and canine osteosarcoma to doxorubicin","volume":"67","author":"Wittenburg","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180107222224_b26-or-31-03-1453","first-page":"2981","article-title":"Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"key20180107222224_b27-or-31-03-1453","doi-asserted-by":"crossref","first-page":"34940","DOI":"10.1074\/jbc.274.49.34940","article-title":"Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects","volume":"274","author":"Sambucetti","year":"1999","journal-title":"J Biol Chem"},{"key":"key20180107222224_b28-or-31-03-1453","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/bbrc.1997.6255","article-title":"Butyrate stimulates cyclin D and p21 and inhibits cyclin-dependent kinase2 expression in HT-29 colonic epithelial cells","volume":"232","author":"Siavoshian","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180107222224_b29-or-31-03-1453","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00280-008-0747-1","article-title":"Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas","volume":"63","author":"Erlich","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180107222224_b30-or-31-03-1453","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J"},{"key":"key20180107222224_b31-or-31-03-1453","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/jpet.106.106658","article-title":"Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells","volume":"319","author":"Chen","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"key20180107222224_b32-or-31-03-1453","first-page":"4855","article-title":"Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis","volume":"54","author":"Greenblatt","year":"1994","journal-title":"Cancer Res"},{"key":"key20180107222224_b33-or-31-03-1453","first-page":"465","article-title":"Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals","volume":"9","author":"Vaziri","year":"1998","journal-title":"Cell Growth Differ"},{"key":"key20180107222224_b34-or-31-03-1453","doi-asserted-by":"crossref","first-page":"180363","DOI":"10.1155\/2012\/180363","article-title":"Mechanism of growth inhibition of prostate cancer xenografts by valproic acid","volume":"2012","author":"Sidana","year":"2012","journal-title":"J Biomed Biotechnol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2959\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T19:02:11Z","timestamp":1647889331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,31]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,12,31]]},"published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.3892\/or.2013.2959"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2959","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,31]]}}}